Pieris Pharma - PVLA Stock Quotes

The prospects for updating the therapeutic portfolio of Pieris Pharmaceuticals (PVLA) remain blurred, while previous partner failures are already priced in, with the metric standing at 152.71. Geopolitical tensions and raw material supply chain disruptions are hindering international drug trials. The share price history on GURU.Markets confirms the resilience of the asset-light business model, where Anticalin protein development is conducted in the US and Germany, while production is outsourced to third-party contractors.

Price Chart: Pieris Corp (PVLA) for 07/04/2022 - 11/15/2026

Pieris Pharmaceuticals Inc - analytical breakdowns and key metrics (PVLA)

- stock value and consensus price forecast:

Price Chart Pieris Pharmaceuticals|PVLA - Forecast Levels Chart

- issuer market value details:

Market Valuation Pieris Corp|PVLA - Total Company Value

- issuer book value statistics:

Net Assets per Single Share Pieris Pharmaceuticals|PVLA - Company Book Value|Market Capitalization to Book Value Ratio pieris.com|PVLA - Company Total Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

PVLA - Net Income|Projected Future Earnings Pieris Pharmaceuticals|PVLA - P/E Multiple|Projected Price to Earnings Pieris Pharmaceuticals Inc|PVLA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Pieris Pharmaceuticals, Inc.|PVLA - Operating income before deduction of amortization|Earnings per share for the last twelve months Pieris Pharmaceuticals|PVLA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months pieris.com|PVLA - Net earnings per share growth this year|Expected earnings per share growth for next year Pieris Pharmaceuticals

- issuer revenue and sales details:

PVLA - Revenue and Sales Volume|Company Projected Revenue Pieris Pharmaceuticals Inc|PVLA - Market Cap to Revenue Ratio|Forward P/S Multiple Pieris Pharma

Fundamental valuation:pieris.com

The price reflects the market equilibrium between current demand and supply of shares. This indicator captures the objective value of the business through trading history, stripped of informational noise. For Pieris Pharmaceuticals (PVLA), quotes serve as an indicator of market confidence in the success of clinical trials. Extreme capital burn risks directly impact volatility. By analyzing the price chart, an investor can see the valuation dynamics regarding the company's survival.

Analysis of competing companies